Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A catalyst tied to one of Eli Lilly’s high-profile therapies helped lift the stock during the latest session, according to market coverage published Aug. 10.
THE APEX TIMES
THE APEX TIMES
After posting second-quarter results that surged 48% year over year to $23.0 billion, Eli Lilly said it expects further improvement, lifting its outlook as investors recalibrate around the pace of growth.
THE APEX TIMES
The designation for the KRAS G12C inhibitor supports further clinical expansion for Lilly’s investigational cancer medicine in a difficult-to-treat tumor type.
THE APEX TIMES
A market commentary on Aug. 8, 2026 frames Eli Lilly’s GLP-1 position and Viking Therapeutics’ efforts as competing opportunities, but not yet as a direct head-to-head contest.
THE APEX TIMES
In a post-earnings update, Eli Lilly reported 48% revenue growth in the second quarter of 2026, attributing the performance largely to ongoing cardiometabolic medicine demand and indicating it has moved its full-year outlook higher.
THE APEX TIMES
A new report points to Eli Lilly having its next weight-loss-drug FDA submission timing clearly in view, intensifying scrutiny of where Novo Nordisk stands in the anti-obesity market.
THE APEX TIMES
A fresh market comparison frames Pfizer’s next obesity drug candidate, berobenatide, against Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, highlighting how the next wave of anti-obesity treatments could reshape competitive positioning.
THE APEX TIMES
A new Trefis note highlights how derivatives trading can embed competing scenarios for Eli Lilly stock, leaving investors exposed to outcomes that could play out very differently.
THE APEX TIMES
The ruling deals a setback to plaintiffs alleging the companies used legal pressure to block access to compounded versions of GLP-1 therapies.
